NCT06550713 - A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)

Interventions

DRUG

TQB3455 tablet+Azacitidine for Injection

TQB3455 is a selective IDH2 mutant enzyme inhibitor. Azacitidine for injection is a cytosine nucleoside drug that is used for demethylation therapy.

Trial Locations (7)

RECRUITING

Peking University People's Hospital, Beijing

NOT_YET_RECRUITING

Peking University international Hospital, Beijing

NOT_YET_RECRUITING

Harbin The First Hospital, Harbin

NOT_YET_RECRUITING

Shanghai Sixth People's Hospital, Shanghai

NOT_YET_RECRUITING

People's Hospital of Tianjin, Tianjin

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

NOT_YET_RECRUITING

The Second Hospital of Hebei Medical University, Shijiazhuang